{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T13:15:22Z","timestamp":1775135722514,"version":"3.50.1"},"reference-count":0,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[1997,10,1]],"date-time":"1997-10-01T00:00:00Z","timestamp":875664000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Microbial Drug Resistance"],"published-print":{"date-parts":[[1997,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    From 1989 until 1996, during the last 8 years, the proportion of\n                    <jats:italic toggle=\"yes\">Candida (C.) krusei<\/jats:italic>\n                    , and other non-albicans\n                    <jats:italic toggle=\"yes\">Candida spp<\/jats:italic>\n                    . isolated from surveillance cultures and from sterile body sites, was analyzed among 13,758 admissions in a National Cancer Institute. During these admissions a total of 9,042 isolates were prospectively collected from surveillance cultures, and 126 from blood cultures.\n                  <\/jats:p>\n                  <jats:p>\n                    The proportion of\n                    <jats:italic toggle=\"yes\">C. krusei<\/jats:italic>\n                    among all organisms was 12.7% to 16.5% in 1989 through 1991, i.e., before fluconazole was introduced into prophylactic protocols. After the introduction of fluconazole into prophylaxis in acute leukemia in 1992 the incidence of\n                    <jats:italic toggle=\"yes\">C. krusei<\/jats:italic>\n                    was 7.9% to 8.6% during 1994 to 1996. After 5 years of using this drug for prophylaxis, the incidence of\n                    <jats:italic toggle=\"yes\">C. krusei<\/jats:italic>\n                    was lower than before this drug was introduced in our institute. Among yeasts, the most frequently isolated pathogen was still\n                    <jats:italic toggle=\"yes\">Candida albicans<\/jats:italic>\n                    (72.2% of all isolated fungal organisms). Among molds,\n                    <jats:italic toggle=\"yes\">Aspergillus spp<\/jats:italic>\n                    . was the most frequently isolated agent. Analyzing the etiology of proven fungal infections (fungemias) confirmed by positive blood cultures,\n                    <jats:italic toggle=\"yes\">C. albicans<\/jats:italic>\n                    was the most common causative organism in 53.8% of cases.\n                  <\/jats:p>\n                  <jats:p>\n                    The incidence of fungemia due to\n                    <jats:italic toggle=\"yes\">Torulopsis (C.) glabrata<\/jats:italic>\n                    and\n                    <jats:italic toggle=\"yes\">C. krusei<\/jats:italic>\n                    before and after fluconazole introduction did not change. Of 126 organisms isolated from blood cultures, there was no increase in\n                    <jats:italic toggle=\"yes\">T. (C.) glabrata<\/jats:italic>\n                    or\n                    <jats:italic toggle=\"yes\">C. krusei<\/jats:italic>\n                    after introduction of fluconazole for prophylaxis and therapy, and the quoted 6.4% of fungemic episodes remained stable with an incidence of 1 fungemia\/year since 1991. The proportion of\n                    <jats:italic toggle=\"yes\">C. krusei<\/jats:italic>\n                    and\n                    <jats:italic toggle=\"yes\">C. glabrata<\/jats:italic>\n                    among\n                    <jats:italic toggle=\"yes\">Candida spp<\/jats:italic>\n                    . was decreasing in our center between 1989 and 1996. Also, the proportion of non-albicans\n                    <jats:italic toggle=\"yes\">Candida spp<\/jats:italic>\n                    . among isolates decreased from 25.7% in 1990 to 11.9% in 1996.\n                  <\/jats:p>","DOI":"10.1089\/mdr.1997.3.283","type":"journal-article","created":{"date-parts":[[2009,1,29]],"date-time":"2009-01-29T19:18:32Z","timestamp":1233256712000},"page":"283-287","source":"Crossref","is-referenced-by-count":11,"title":["Eight-Year Surveillance of Non-Albicans\n                    <i>Candida spp<\/i>\n                    . in an Oncology Department Prior to and After Fluconazole Had Been Introduced into Antifungal Prophylaxis"],"prefix":"10.1177","volume":"3","author":[{"given":"A.","family":"Kunova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Trupl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Demitrovicova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z.","family":"Jesenska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Grausova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Grey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Pichna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Kralovicova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Sorkovska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Krupova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Spanik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Studena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Koren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"V.","family":"Krcmery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2009,1,29]]},"container-title":["Microbial Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.1997.3.283","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.1997.3.283","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T12:21:25Z","timestamp":1775132485000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/mdr.1997.3.283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,10]]},"references-count":0,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1997,10]]}},"alternative-id":["10.1089\/mdr.1997.3.283"],"URL":"https:\/\/doi.org\/10.1089\/mdr.1997.3.283","relation":{},"ISSN":["1076-6294","1931-8448"],"issn-type":[{"value":"1076-6294","type":"print"},{"value":"1931-8448","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,10]]}}}